- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04893187
A Phase 1 Study of SSS17 in Healthy Subjects.
A Phase 1 Study to Evaluate the Tolerance, Safety, Pharmacokinetics and Pharmacodynamics of Oral Administration of SSS17 in Chinese Healthy Adult Subjects With Single and Multiple Dose Escalation and the Effect of Food on the Pharmacokinetics of SSS17.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The study will enroll healthy volunteers from a single academic medical center in China. All participants will be informed about the study and potential risks and required to provide written informed consent prior to undergoing study-related procedures.The study will be divided into 3 parts.
Part 1: Subjects will be allocated 2:8 to receive placebo or SSS17(it was only 2:2 in 5mg dose group),which will be administered by oral route with single dose. At each dose, tolerability, safety, PK and PD characteristics will be investigated.
Part 2: Subjects will be allocated 2:8 to receive placebo or SSS17, which will be administered by oral route with multiple dose. At each cohort,tolerability, safety, PK and PD characteristics will be investigated.
Part 3: The subjects will receive two cycles of treatment, one is given on an empty stomach, the other is given after a high-fat meal, with an interval of 15 days.
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
- Navn: Director Li
- Telefonnummer: 18028886429
- E-mail: 747560265@qq.com
Undersøgelse Kontakt Backup
- Navn: Professor Fang, Ph.D
- Telefonnummer: 13701165926
- E-mail: fygk7000@163.com
Studiesteder
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510700
- Rekruttering
- The Fifth Affiliated Hospital of Guangzhou Medical University
-
Kontakt:
- Yi Fang, Ph.D
- Telefonnummer: 13701165926
- E-mail: fygk7000@163.com
-
Kontakt:
- Yongmei Li, Ph.D
- Telefonnummer: 13640691018
- E-mail: Liyongmei_gz@126.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Chinese healthy adult subjects aged 18-45 years (including the boundary value) at the time of signing the informed consent were male and female;
- In the screening period, the weight of male subjects was more than or equal to 50.0 kg; Female weight ≥ 45.0 kg; Body mass index (BMI) ranged from 19.0 kg / m2 to 26.0 kg / m2 (including boundary value); BMI = weight kg / height m2);
- Within 6 months from the date of signing the informed consent to the end of the trial, female subjects agreed to take reliable measures to avoid pregnancy and ensure no birth plan, while male subjects agreed to take reliable measures to avoid pregnancy and ensure no birth plan;
- Willing to participate in the study and sign a written informed consent, able to communicate well with the researchers, and agreed to follow the requirements of the trial protocol and follow-up on schedule.
Exclusion Criteria:
- Participated in other drug clinical trials within 3 months before screening;
- Have any clinical history of serious diseases or are suffering from related diseases, including but not limited to digestive system (such as diarrhea, vomiting, inflammatory bowel disease, hemorrhoids, acute gastritis, peptic ulcer, acute and chronic gastrointestinal disorders with obvious digestive and absorption disorders), cardiovascular system, respiratory system, urinary system, musculoskeletal system, endocrine system, gastrointestinal tract diseases, etc Diseases of nervous and mental system, blood system, immune system, etc; A history of any disease or thrombotic disease or vascular malformation that increases the risk of bleeding; Patients with dysphagia;
- Allergic constitution, known allergic to test drug ingredients or allergic history to any drug or food (mango, shrimp, crab, lobster, etc.) or pollen allergy history;
- Those who smoke more than 5 cigarettes / day or the same amount of tobacco after inquiry, or who can not ban smoking during the trial period; Or alcohol consumption per week is equal to 14 units (1 units 25mL wine Baijiu / 100mL wine / 285mL beer), or those who can not prohibit alcohol during the test period;
- Have a history of drug abuse or drug abuse;
- Within 6 months, there were fertility planning, sperm donation and egg donation planning;
- Patients with lactose intolerance (those who have had diarrhea after drinking milk);
- Those who have special requirements for diet and cannot accept unified diet;
- Blood donors or massive blood loss (≥ 400ml), EPO treatment, blood transfusion or use of blood products within 3 months before screening;
- Those vaccinated within 8 weeks before screening or during the study period;
- There was a history of acupuncture and blood sickness; Or with orthostatic hypotension;
- Those who have participated in and used the trial drug;Those who have used any prescription drug, over-the-counter drug, Chinese herbal medicine, vitamins or health care products within 14 days before screening and whose time is less than 5 half-life of the drug or less than 2 weeks (whichever is the longest);
- The serum pregnancy test of lactating and pregnant women, or female volunteers of childbearing age was positive;
- The results of physical examination, chest X-ray, color Doppler ultrasound, electrocardiogram and laboratory examination were abnormal and clinically significant; Or hemoglobin of male subjects was more than 175.0 g / L; Or hemoglobin of female subjects was more than 150.0 g / L; Or hemoglobin of male and female were less than 113g / L;
- Within 48 hours before enrollment, those who took any special diet that affected the absorption, distribution, metabolism and excretion of drugs, including pitaya, mango, grapefruit, lime, carambola or food or drink prepared from them, chocolate, and any food or drink containing caffeine;
- Urine drug screening test was positive;
- Alcohol breath test was positive within 24 hours before administration;
- The researchers think that there are other cases that are not suitable for the trial.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Part 1: Single Dose Escalation SSS17
Escalating doses of SSS17, single dose administration
|
SSS17 is a novel small molecule compound which stimulates erythropoiesis through inhibition of hypoxiainducible factor- prolyl hydroxylases( HIF-PH).
It is being developed for the treatment of anemia in patients with chronic kidney disease.
|
Placebo komparator: Part 1: Single Dose Escalation matching Placebo
Escalating doses of matching placebo, single dose administration
|
Matchet placebo.
|
Eksperimentel: Part 2: Multiple Dose Escalation SSS17
Escalating doses of SSS17, multiple dose administration
|
SSS17 is a novel small molecule compound which stimulates erythropoiesis through inhibition of hypoxiainducible factor- prolyl hydroxylases( HIF-PH).
It is being developed for the treatment of anemia in patients with chronic kidney disease.
|
Placebo komparator: Part 2: Multiple Dose Escalation matching Placebo
Escalating doses of matching placebo, multiple dose administration
|
Matchet placebo.
|
Eksperimentel: Part 3: Treatment Sequence 1 (A to B)
The subjects in the first cycle received oral administration of SSS17 on an empty stomach, and subjects in the second cycle received oral administration of SSS17 after a high-fat meal
|
SSS17 is a novel small molecule compound which stimulates erythropoiesis through inhibition of hypoxiainducible factor- prolyl hydroxylases( HIF-PH).
It is being developed for the treatment of anemia in patients with chronic kidney disease.
|
Eksperimentel: Part 3: Treatment Sequence 2 (B to A)
The subjects in the first cycle received oral administration of SSS17 after a high-fat meal, and the subjects in the second cycle received oral administration of SSS17 on an empty stomach
|
SSS17 is a novel small molecule compound which stimulates erythropoiesis through inhibition of hypoxiainducible factor- prolyl hydroxylases( HIF-PH).
It is being developed for the treatment of anemia in patients with chronic kidney disease.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Part 1: AEs
Tidsramme: Baseline up to Days 15
|
Assessment AEs by frequency and severity in the part 1
|
Baseline up to Days 15
|
Part 1: Maximum plasma concentration (Cmax) of SSS17
Tidsramme: Up to 336 hours post-dose
|
Plasma samples will be collected and Cmax will be assessed in the part 1
|
Up to 336 hours post-dose
|
Part 1: Area under the concentration-time curve (AUC) of plasma concentration of SSS17
Tidsramme: Up to 336 hours post-dose
|
Plasma samples will be collected and the AUC from zero to infinity will be assessed in the part 1
|
Up to 336 hours post-dose
|
Part 1: Time-to-Cmax (Tmax) of SSS 17
Tidsramme: Up to 336 hours post-dose
|
Plasma samples will be collected and the Tmax will be assessed from the concentration-time curve in the part 1
|
Up to 336 hours post-dose
|
Part 1: Elimination terminal half-life (t1/2) of SSS17
Tidsramme: Up to 336 hours post-dose
|
Plasma samples will be collected and the t1/2 will be assessed in the part 1
|
Up to 336 hours post-dose
|
Part 1: . Total amount of SSS17 excreted in urine over 72 hours (Ae0-72)
Tidsramme: Up to 72 hours post-dose
|
Urine sample will be collected at pre-specified intervals and Ae0-72 will be assessed in the part 1
|
Up to 72 hours post-dose
|
Part 1: Fraction of SSS17 excretion during each collection interval (Fe0-72)
Tidsramme: Up to 72 hours post-dose
|
Urine sample will be collected at pre-specified intervals and Fe0-72 will be assessed in the part 1
|
Up to 72 hours post-dose
|
Part 1: Renal clearance (CLR) of SSS17
Tidsramme: Up to 72 hours post-dose
|
Urine sample will be collected at pre-specified intervals and CLR will be assessed in the part 1
|
Up to 72 hours post-dose
|
Part 2: AEs
Tidsramme: Up to Days 33 or 57
|
Assessment AEs by frequency and severity in the part 2
|
Up to Days 33 or 57
|
Part 2: Steady state minimal concentration (Css_min) of SSS17
Tidsramme: Up to Days 33 or 57
|
Plasma samples will be collected and Css_min will be assessed in the part 2
|
Up to Days 33 or 57
|
Part 2: Steady state maximum concentration (Css_max) of SSS17
Tidsramme: Up to Days 33 or 57
|
Plasma samples will be collected and Css_max will be assessed in the part 2
|
Up to Days 33 or 57
|
Part 2: Steady state average concentration (Css_av) of SSS17
Tidsramme: Up to Days 33 or 57
|
Plasma samples will be collected and Css_av will be assessed in the part 2
|
Up to Days 33 or 57
|
Part 2: Area under the concentration-time curve of plasma concentration of SSS17 within the interval of administration after reaching steady state (AUC0-τ)
Tidsramme: Up to Days 33 or 57
|
Plasma samples will be collected and the AUC from zero to τ will be assessed
|
Up to Days 33 or 57
|
Part 3: Maximum plasma concentration (Cmax) of SSS17
Tidsramme: Up to Days 44
|
Plasma samples will be collected and Cmax will be assessed in the part 3
|
Up to Days 44
|
Part 3: Area under the concentration-time curve (AUC) of plasma concentration of SSS17
Tidsramme: Up to Days 44
|
Plasma samples will be collected and the AUC from zero to infinity will be assessed in the part 3
|
Up to Days 44
|
Part 3: Time-to-Cmax (Tmax) of SSS 17
Tidsramme: Up to Days 44
|
Plasma samples will be collected and the Tmax will be assessed from the concentration-time curve in the part 3
|
Up to Days 44
|
Part 3: Elimination terminal half-life (t1/2) of SSS17
Tidsramme: Up to Days 44
|
Plasma samples will be collected and the t1/2 will be assessed in the part 3
|
Up to Days 44
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Part 1: EPO concentrations
Tidsramme: Up to 168 hours post-dose
|
Change of EPO concentrations from baseline following SSS17 in the part 1
|
Up to 168 hours post-dose
|
Part 1: VEGF concentrations
Tidsramme: Up to 168 hours post-dose
|
Change of VEGF concentrations from baseline following SSS17 in the part 1
|
Up to 168 hours post-dose
|
Part 1: Change of hepcidin from baseline
Tidsramme: Up to 168 hours post-dose
|
Change of serum hepcidin concentrations from baseline following SSS17 in the part 1
|
Up to 168 hours post-dose
|
Part 1: Change of RTC from baseline
Tidsramme: Baseline up to Days 15
|
Change of RTC from baseline following SSS17 in the part 1
|
Baseline up to Days 15
|
Part 1: Change of RBC from baseline
Tidsramme: Baseline up to Days 15
|
Change of RBC from baseline following SSS17 in the part 1
|
Baseline up to Days 15
|
Part 1: Change of Hgb from baseline
Tidsramme: Baseline up to Days 15
|
Change of Hgb from baseline following SSS17 in the part 1
|
Baseline up to Days 15
|
Part 2: EPO concentrations
Tidsramme: Up to Days 33 or 57
|
Change of EPO concentrations from baseline following SSS17 in the part 2
|
Up to Days 33 or 57
|
Part 2: VEGF concentrations
Tidsramme: Up to Days 33 or 57
|
Change of VEGF concentrations from baseline following SSS17 in the part 2
|
Up to Days 33 or 57
|
Part 2: Change of hepcidin from baseline
Tidsramme: Up to Days 33 or 57
|
Change of serum hepcidin concentrations from baseline following SSS17 in the part 2
|
Up to Days 33 or 57
|
Part 2: Change of RTC from baseline
Tidsramme: Baseline up to Days 33 or 57
|
Change of RTC from baseline following SSS17 in the part 2
|
Baseline up to Days 33 or 57
|
Part 2: Change of RBC from baseline
Tidsramme: Baseline up to Days 33 or 57
|
Change of RBC from baseline following SSS17 in the part 2
|
Baseline up to Days 33 or 57
|
Part 2: Change of Hgb from baseline
Tidsramme: Baseline up to Days 33 or 57
|
Change of Hgb from baseline following SSS17 in the part 2
|
Baseline up to Days 33 or 57
|
Part 3: AEs
Tidsramme: Up to Days 44
|
Assessment AEs by frequency and severity in the part 3
|
Up to Days 44
|
Part 3: EPO concentrations
Tidsramme: Up to Days 44
|
Change of EPO concentrations from baseline following SSS17 in the part 3
|
Up to Days 44
|
Part 3: VEGF concentrations
Tidsramme: Up to Days 44
|
Change of VEGF concentrations from baseline following SSS17 in the part 3
|
Up to Days 44
|
Part 3: Change of hepcidin from baseline
Tidsramme: Up to Days 44
|
Change of serum hepcidin concentrations from baseline following SSS17 in the part 3
|
Up to Days 44
|
Part 3: Change of RTC from baseline
Tidsramme: Baseline up to Days 44
|
Change of RTC from baseline following SSS17 in the part 3
|
Baseline up to Days 44
|
Part 3: Change of RBC from baseline
Tidsramme: Baseline up to Days 44
|
Change of RBC from baseline following SSS17 in the part 3
|
Baseline up to Days 44
|
Part 3: Change of Hgb from baseline
Tidsramme: Baseline up to Days 44
|
Change of Hgb from baseline following SSS17 in the part 3
|
Baseline up to Days 44
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- SYSS-SSS17-UND-I-02
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Placebo
-
SamA Pharmaceutical Co., LtdUkendtAkut bronkitis | Akut øvre luftvejsinfektionKorea, Republikken
-
National Institute on Drug Abuse (NIDA)AfsluttetBrug af cannabisForenede Stater
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyAfsluttetMandlige forsøgspersoner med type II-diabetes (T2DM)Tyskland
-
Heptares Therapeutics LimitedAfsluttetFarmakokinetik | SikkerhedsproblemerDet Forenede Kongerige
-
Texas A&M UniversityNutraboltAfsluttetGlucose and Insulin Response
-
Regado Biosciences, Inc.AfsluttetSund frivilligForenede Stater
-
Longeveron Inc.AfsluttetHypoplastisk venstre hjerte syndromForenede Stater
-
ItalfarmacoAfsluttetBeckers muskeldystrofiHolland, Italien
-
West Penn Allegheny Health SystemAfsluttetAstma | Allergisk rhinitisForenede Stater